亚洲高潮,久久精品电影网,国产黄色在线看,男女网站在线看,天天综合网~永久入口,六月婷婷在线,国产熟女性爱视频,一区二线视频

<button id="eiezk"><video id="eiezk"></video></button>

產(chǎn)品名稱

Recombinant Human IFN-α2 (carrier-free) from BIOLEGEND

產(chǎn)品貨號

592702

產(chǎn)品價格

現(xiàn)貨詢價，電話：010-67529703

產(chǎn)品規(guī)格

10 μg

產(chǎn)品品牌

BIOLEGEND

產(chǎn)品概述

產(chǎn)品詳情

Edit	&nbsp
Product Name	Recombinant Human IFN-α2 (carrier-free)
Description	Interferons are divided into type I, II, and III. Type I IFNs (IFN-α and IFN-β) are most abundant in number, distribution, and expression. Also, they are highly conserved among mammals in both structure and function. IFN-α2 has been used in the treatment of cancer such as bladder cancer, hepatocellular carcinoma, and leukemia. IFN-α2 augments the suppressed immune functions in patients with head and neck squamous cell carcinoma (HNSCC). IFN-α2 initiated T and NK cell mediated cytotoxicity of tumor cells through IFNγ dependent and independent mechanisms. IFN-α2 enhances suppressed T cell cytotoxicity by stimulation of the perforin-granzyme B system (IFNγ dependent). Also, IFN-α2 induces the expression of perforin-granzyme B in NK cells (NK mediated cytotoxicity, IFNγ independent). In a preliminary study, IFN-α2 appears to be an effective immunostimulator and impacts the clinical outcome in tongue squamous cell carcinoma patients. IFN-α had been used in the treatment of chronic hepatitis C (CHC); nevertheless, IFN-α is relatively unstable and requires frequent parenteral administration. Pegylation of IFN-α, polyethylene glycol (PEG)-IFN-α, reduces in vitro activity but increase the stability and plasma half-life of IFN-α; therefore, PEG-IFN-α has replaced IFN-α in CHC treatment.
Size	10 μg
Concentration	n/a
Applications	BA
Other Names	IFN-alpha 2B, IFN-alphaA, IFNA2, IFNA2B
Gene, Accession, CAS #	Gene ID: 3440
Catalog #	592702
Price
Order / More Info	Recombinant Human IFN-α2 (carrier-free) from BIOLEGEND
Product Specific References	n/a
產(chǎn)品資料

<button id="eiezk"><video id="eiezk"></video></button>